Dr Elizabeth O'Donnell speaks to ecancer about her ASCO 2020 Virtual Meeting presentation on denosumab in multiple myeloma (MM) patients with renal insufficiency.
The phase II, single-arm study aimed to address the unmet need for the management of skeletal complications in these patients.
Dr O'Donnell reports that denosumab can be safely administered in this population, however, there are concerns over hypocalcemia despite prophylactic calcium dosing.
Dr O'Donnell stresses that this demonstrates the importance of studying this population further and outlines the next steps for the study.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.